Page last updated: 2024-12-07

2-chlorobenzenesulfonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID81410
CHEMBL ID367983
SCHEMBL ID121865
MeSH IDM0136986

Synonyms (47)

Synonym
2-chlorobenzenesulphonamide
EN300-15723
einecs 230-156-7
o-chlorobenzenesulphonamide
nsc 62927
unii-4bt2i28a0c
4bt2i28a0c ,
2-chlorobenzenesulfonamide
SDCCGMLS-0064580.P001
o-chlorobenzenesulfonamide
benzenesulfonamide, 2-chloro-
benzenesulfonamide, o-chloro-
nsc-62927
nsc62927
6961-82-6
2-chlorobenzenesulfonamide, 98%
C1990
2-chloro-benzenesulfonamide
CHEMBL367983
jccbzcmsyuscfm-uhfffaoysa-
inchi=1/c6h6clno2s/c7-5-3-1-2-4-6(5)11(8,9)10/h1-4h,(h2,8,9,10)
AKOS000138429
A836565
A-4097 ,
dtxsid2044979 ,
NCGC00256231-01
cas-6961-82-6
tox21_301624
dtxcid0024979
2-chlorobenzene-1-sulfonamide
12002-50-5
FT-0611910
SCHEMBL121865
2WEH
2-chlorobenzene sulphonamide
2-chlorophenylsulfonamide
cambridge id 5109421
W-104613
STR08928
mfcd00051974
SY035730
Z45415618
AMY21854
AC8083
Q27259385
CS-W015837
benzenesulfonamide, chloro- (6ci,7ci,8ci,9ci)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency24.33650.000657.913322,387.1992AID1259377
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency21.87240.023723.228263.5986AID743223
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Carbonic Anhydrase 2Homo sapiens (human)Kd1.12500.83900.98201.1250AID977611
Chain A, Carbonic Anhydrase 2Homo sapiens (human)Kd1.12500.83900.98201.1250AID977611
Chain A, Carbonic Anhydrase 2Homo sapiens (human)Kd1.12500.83900.98201.1250AID977611
Chain A, Carbonic Anhydrase 2Homo sapiens (human)Kd1.12500.83900.98201.1250AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID239935Inhibition constant against carbonic anhydrase2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Novel use of chemical shift in NMR as molecular descriptor: a first report on modeling carbonic anhydrase inhibitory activity and related parameters.
AID237572Diuretic activity was determined2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzene sulfonamides: a molecular connectivity approach.
AID244692Diuretic activity was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Novel use of chemical shift in NMR as molecular descriptor: a first report on modeling carbonic anhydrase inhibitory activity and related parameters.
AID239922Inhibitory activity against carbonic anhydrase2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzene sulfonamides: a molecular connectivity approach.
AID1339468Inhibition of wild type PI3K p110alpha/p85alpha niSH2 (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to contr2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
AID70529Inhibitory activity against bovine erythrocyte B enzyme1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
The binding of benzenesulfonamides to carbonic anhydrase enzyme. A molecular mechanics study and quantitative structure-activity relationships.
AID1339469Inhibition of full length PI3Kalpha (unknown origin) assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to control2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
AID237422Partition coefficient (logP)2004Bioorganic & medicinal chemistry letters, Nov-15, Volume: 14, Issue:22
Topological modeling of lipophilicity, diuretic activity, and carbonic inhibition activity of benzene sulfonamides: a molecular connectivity approach.
AID237031Partition coefficient (logP)2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Novel use of chemical shift in NMR as molecular descriptor: a first report on modeling carbonic anhydrase inhibitory activity and related parameters.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2009ChemMedChem, Dec, Volume: 4, Issue:12
Thermodynamic optimisation in drug discovery: a case study using carbonic anhydrase inhibitors.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (20.00)18.7374
1990's1 (10.00)18.2507
2000's3 (30.00)29.6817
2010's3 (30.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]